


## Tulopafant

<b>Cat. No.:</b>	HY-101594
<b>CAS No.:</b>	116289-53-3
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>19</sub> N <sub>3</sub> O <sub>2</sub> S
<b>Molecular Weight:</b>	425.5
<b>Target:</b>	Platelet-activating Factor Receptor (PAFR)
<b>Pathway:</b>	GPCR/G Protein
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Tulopafant is a platelet activating factor (PAF) antagonist.
<b>In Vitro</b>	Preincubation of neutrophils with Tulopafant (RP 59227) results in a concentration-dependent decrease in chemiluminescence produced by PAF primed cells <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	Tulopafant (RP 59227) effectively reduces myocardial infarct size and reduces the incidence of ischemia and reperfusion-induced arrhythmias in barbital-anesthetized dogs <sup>[1]</sup> . Histological examination reveals marked diminution of both interstitial hemorrhage and deposition of platelet and granulocytes in capillaries of cardiac xenografts when recipient animals are pretreated with Tulopafant <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Auchampach JA, et al. Effect of the platelet-activating factor antagonist RP 59227 (Tulopafant) on myocardial ischemia/reperfusion injury and neutrophil function. *Basic Res Cardiol.* 1998 Oct;93(5):361-71.

[2]. O'Hair DP, et al. Tulopafant, a PAF receptor antagonist, increases capillary patency and prolongs survival in discordant cardiac xenotransplants. *J Lipid Mediat.* 1993 May;7(1):79-84.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA